KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Assets (2016 - 2025)

Rigel Pharmaceuticals has reported Current Assets over the past 16 years, most recently at $240.2 million for Q4 2025.

  • For Q4 2025, Current Assets rose 77.77% year-over-year to $240.2 million; the TTM value through Dec 2025 reached $240.2 million, up 77.77%, while the annual FY2025 figure was $240.2 million, 77.77% up from the prior year.
  • Current Assets for Q4 2025 was $240.2 million at Rigel Pharmaceuticals, up from $214.9 million in the prior quarter.
  • Over five years, Current Assets peaked at $240.2 million in Q4 2025 and troughed at $92.5 million in Q1 2024.
  • A 5-year average of $140.0 million and a median of $127.8 million in 2022 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: plummeted 35.45% in 2022 and later skyrocketed 101.87% in 2025.
  • Year by year, Current Assets stood at $154.5 million in 2021, then decreased by 24.97% to $115.9 million in 2022, then fell by 14.35% to $99.3 million in 2023, then surged by 36.1% to $135.1 million in 2024, then soared by 77.77% to $240.2 million in 2025.
  • Business Quant data shows Current Assets for RIGL at $240.2 million in Q4 2025, $214.9 million in Q3 2025, and $175.4 million in Q2 2025.